ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 113 citations in OpenAlex.
- Programmable genetic control of tumor-colonizingbioRxiv : the preprint server for biology · 2026Article
- Tracking the rotational dynamics of Chlamydomonas reinhardtii across culture days using optical tweezers.European biophysics journal : EBJ · 2026Article
- The intratumoral microbiota in breast cancer: from basic research to clinical translation.Gut microbes · 2025Review
- Micro/Nano-Motors for Enhanced Tumor Diagnosis and Therapy.International journal of molecular sciences · 2025Review
- EngineeredCancers · 2025Review
- Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors.International journal of nanomedicine · 2025Article
- Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.Discover oncology · 2024Review
- Veillonella parvula as an anaerobic lactate-fermenting bacterium for inhibition of tumor growth and metastasis through tumor-specific colonization and decrease of tumor's lactate level.Scientific reports · 2024Article
- The application of bacteria-nanomaterial hybrids in antitumor therapy.Journal of nanobiotechnology · 2024Review
- Review
- Review
- Bacterial therapies at the interface of synthetic biology and nanomedicine.Nature reviews bioengineering · 2024Article
- Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications.Microbiome research reports · 2024Review
- Intratumor microbiome: selective colonization in the tumor microenvironment and a vital regulator of tumor biology.MedComm · 2023Review
- Article
- Refined control of CRISPR-Cas9 gene editing inFrontiers in immunology · 2023Article
- Understanding and harnessing triple-negative breast cancer-related microbiota in oncology.Frontiers in oncology · 2022Review
- Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.Vaccines · 2021Review
- Microbiome in drug resistance to colon cancer.Current opinion in physiology · 2021Article
- The Gut‒Breast Axis: Programming Health for Life.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Certain bacteria have emerged as biological gene vectors with natural tumor specificity, capable of specifically delivering genes or gene products to the tumor environment when intravenously (i.v.) administered to rodent models. We show for the first time that oral administration of bacteria to mice resulted in their translocation from the gastrointestinal tract (GIT) with subsequent homing to and replication specifically in tumors. The commensal, nonpathogenic Bifidobacterium breve UCC2003 harboring a plasmid expressing lux fed to mice bearing subcutaneous (s.c.) tumors were readily detected specifically in tumors, by live whole-body imaging, at levels similar to i.v. administration. Reporter gene expression was visible for >2 weeks in tumors. Mice remained healthy throughout experiments. Cytokine analyses indicated a significant upregulation of interferon-gamma (IFN-gamma) in the GIT of bifidobacteria-fed mice, which is associated with increases in epithelial permeability. However, B. breve feeding did not increase systemic levels of other commensal bacteria. The presence of tumor was not necessary for translocation to systemic organs to occur. These findings indicate potential for safe and efficient gene-based treatment and/or detection of tumors via ingestion of nonpathogenic bacteria expressing therapeutic or reporter genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.